New immune duo shows promise in preventing Post-Transplant infection
NCT ID NCT04934527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to prevent CMV infection in 42 CMV-positive kidney transplant patients. Researchers combined an antibody infusion with a specific type of immune cell (gamma delta T cells) to see if it could stop the virus from reactivating. The goal was to find a safer alternative to standard antiviral drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Pellegrin
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications